Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.3K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.3K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

55
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
55
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

42.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity.

iScience·2026
Same author

Protocol for multiplexed detection of antibody binding to cell-surface-expressed hemagglutinin by flow cytometry.

STAR protocols·2026
Same author

Antibody-mediated diversification of primary and secondary humoral immune responses.

The Journal of experimental medicine·2026
Same author

B lymphocyte protein factories produced by hematopoietic stem cell gene editing.

Science (New York, N.Y.)·2026
Same author

Autologous neutralizing antibodies and polyfunctional T cells contribute to long-term HIV-1 post-intervention control.

Nature immunology·2026
Same author

B lymphocytes that enter the germinal center late preferentially differentiate into memory cells that recognize subdominant epitopes.

Immunity·2026

Related Experiment Video

Updated: Apr 25, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.2K

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Ariel Halper-Stromberg1, Ching-Lan Lu2, Florian Klein1

  • 1Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.

Cell
|August 19, 2014
PubMed
Summary

Broadly neutralizing antibodies (bNAbs) combined with multiple HIV-1 transcription inducers show promise in reducing latent HIV-1 reservoirs. This combination therapy, tested in humanized mice, offers a potential strategy against persistent HIV-1 infection.

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

14.1K
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

7.5K

Related Experiment Videos

Last Updated: Apr 25, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.2K
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

14.1K
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

7.5K

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Latent reservoirs of HIV-1-infected cells are a major barrier to curing HIV-1, as they are resistant to antiretroviral therapies (ART).
  • Current strategies like "shock and kill" aim to eliminate these reservoirs but have not yet succeeded in vivo.
  • Latently infected cells are long-lived, evade immune detection, and can proliferate, making them difficult to eradicate.

Purpose of the Study:

  • To investigate the efficacy of broadly neutralizing antibodies (bNAbs) in combination with viral transcription inducers to impact the HIV-1 reservoir.
  • To evaluate therapeutic strategies for reducing latent HIV-1 reservoirs in a humanized mouse model.

Main Methods:

  • Humanized mice models were used to study the establishment and maintenance of HIV-1 reservoirs.
  • The study assessed the impact of bNAbs alone, bNAbs with single inducers, and bNAbs with combinations of inducers.
  • Viral rebound was measured to assess the effectiveness of different therapeutic combinations.

Main Results:

  • Broadly neutralizing antibodies (bNAbs) were found to interfere with the establishment of silent HIV-1 reservoirs through Fc-FcR-mediated mechanisms.
  • In established infections, bNAbs or bNAbs plus single inducers did not prevent viral rebound.
  • A synergistic effect was observed when bNAbs were combined with multiple inducers acting via independent mechanisms, leading to a decrease in the reservoir size as indicated by viral rebound.

Conclusions:

  • Combinations of inducers and bNAbs represent a promising therapeutic strategy for impacting both the establishment and maintenance of HIV-1 reservoirs.
  • This approach shows potential for reducing latent HIV-1 reservoirs, a critical step towards an HIV-1 cure.
  • Further research into synergistic combinations of bNAbs and inducers is warranted for clinical translation.